April 22, 2018 6:43 PM ET

Pharmaceuticals

Company Overview of Quark Pharmaceuticals, Inc.

Company Overview

Quark Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of novel RNAi-based therapeutics. The company offers QPI-1002, a synthetic chemically modified siRNA to reduce p53 RNA and protein levels; QPI-1007, a neuro-protective agent for the treatment of optic neuropathies that results in the death of retinal ganglion cells; and PF-655 for the treatment of diabetic macular edema and the other in patients with wet and age-related macular degeneration. It also provides preclinical pipeline targeting unmet medical needs. Quark Pharmaceuticals, Inc. has discovery and development collaboration with Transplant Genomics Inc. The company was formerl...

6501 Dumbarton Circle

Fremont, CA 94555

United States

Founded in 1993

97 Employees

Phone:

510-402-4020

Fax:

510-402-4021

Key Executives for Quark Pharmaceuticals, Inc.

Founder, Chief Executive Officer, President and Director
Age: 71
Chief Financial Officer
Chief Operating Officer
Age: 59
Senior Vice President of Strategy & Planning
Age: 65
Chief Medical Officer
Age: 51
Compensation as of Fiscal Year 2017.

Quark Pharmaceuticals, Inc. Key Developments

Quark Pharmaceuticals, Inc. Presents at Drug Discovery for Rare Diseases Symposium at OPT Congress, Mar-28-2018 01:50 PM

Quark Pharmaceuticals, Inc. Presents at Drug Discovery for Rare Diseases Symposium at OPT Congress, Mar-28-2018 01:50 PM. Venue: Boston Marriott Cambridge, Cambridge, Massachusetts, United States. Speakers: Elena Feinstein, Chief Scientific Officer.

Quark Pharmaceuticals, Inc. Presents at CHI’s Third Annual Oligonucleotide Discovery and Delivery Conference, Mar-26-2018 through Mar-28-2018

Quark Pharmaceuticals, Inc. Presents at CHI’s Third Annual Oligonucleotide Discovery and Delivery Conference, Mar-26-2018 through Mar-28-2018. Venue: Boston Marriott Cambridge, Cambridge, Massachusetts, United States. Presentation Date & Speakers: Mar-26-2018, Elena Feinstein, Chief Scientific Officer. Mar-28-2018, Elena Feinstein, Chief Scientific Officer.

Quark Pharmaceuticals, Inc. to Present Positive Phase 2 Efficacy and Safety Results of QPI-1002, A siRNATargeting P53, for Prevention of Acute Kidney Injury Following Cardiac Surgery

Quark Pharmaceuticals Inc. announced that positive results from a Phase 2 clinical study on its lead program QPI-1002 will be presented as an oral abstract at the EuroTIDES conference being held in Vienna AustriaNovember 7-10, 2017. The presentation titled Phase 2 Efficacy And Safety Results Of QPI-1002 (QPI), A siRNA Targeting p53, For Prevention Of Acute Kidney Injury (AKI) Following Cardiac Surgery (CS), will be delivered by Dr. Shai Erlich, CMO and President of Quark Pharmaceuticals US Operations during the 5pm (CET) session on November 8, 2017. About QPI-1002: QPI-1002 is the first systemic siRNA drug to enter human clinical trials and to complete several well-controlled clinical studies with efficacy endpoints that were conducted in hundreds of patients. It is an investigational drug designed to temporarily inhibit the expression of the pro-apoptotic gene, p53, to protect normal cells from death stemming from acute tissue injury. Preclinical studies have shown that p53-targeted siRNAs can protect kidneys from ischemia-reperfusion injury in a variety of clinically relevant animal models. QPI-1002 has been granted Orphan Drug designation in the USA and Europe for prophylaxis of delayed graft function following kidney transplantation. Under an August 2010 agreement, Novartis has an exclusive worldwide license option for the development and commercialization of QPI-1002.

Similar Private Companies By Industry

Company Name Region
Praetego, Inc. United States
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Quark Pharmaceuticals, Inc., please visit www.quarkpharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.